News / Taiwan / economic_daily
Bone Pharma Expands Global Footprint with 'RevoCart' Licensing and OIF Clinical Trials
Health Technology · Biotechnology · economic_daily · 2026-08-31
6733
Bone Pharma reported improved financial results and outlined plans for global licensing of its 'RevoCart' product and upcoming Phase III trials for OIF in Japan.
What Happened
Global Expansion: Bone Pharma is actively pursuing global licensing opportunities for its flagship product, 'RevoCart,' with ongoing negotiations with U.S. orthopedic firms. Additionally, the company is preparing for the Phase III clinical trial of its Bone Growth Factor (OIF) in Japan, with patient enrollment scheduled to begin in the first quarter of 2027.
Financial Improvement: The company reported a 14.22% year-over-year increase in consolidated revenue for the first half of the year, reaching NT$114 million. Net losses have narrowed compared to the same period last year, reflecting improved operational efficiency and the successful commercialization of its product portfolio.
R&D Strategy: Chairman Chen De-li emphasized a dual-track strategy aimed at balancing short-term revenue growth with long-term R&D value. Beyond its primary offerings, the company is also focusing on developing products for severe infections to diversify its pipeline.
Future Outlook: As clinical trials progress and international licensing discussions continue, Bone Pharma is transitioning into a more commercially viable biotech entity. The company remains committed to optimizing its operational structure to enhance profitability while sustaining its research and development momentum.
Read original
More in Health Technology
Health Technology · cnbc · 2026-08-31
Eli Lilly is deploying its obesity-driven cash reserves to acquire Merida Biosciences for $2.875 billion, while GE Vernova shares face pressure from SpaceX manufacturing rumors.
.SPX, LLY, GEV, HWM, @CL26V, @LCO26X, XLE, PEP, XLV, MDT, XLK, XLU
Health Technology · cnbc · 2026-08-31
President Trump is set to announce new agreements with nearly a dozen pharmaceutical companies to lower medication costs by aligning prices with foreign markets.
NVO, NVO, PFE, LLY, XBI, IHE
Health Technology · economic_daily · 2026-08-31
While contact lens manufacturer Vision Precision projects quarterly earnings growth, foreign investors continue to offload shares, sparking market debate.
Latest in Taiwan
Electronic Technology · economic_daily · 2026-08-31
Key financial updates include Nvidia and Alphabet's investment in MediaTek, TSMC's bullish AI outlook, strong bank earnings, and the impact of US trade policies.
2330, 2454
Electronic Technology · economic_daily · 2026-08-31
Taiwan's stock market surged 6.9% in August, outperforming all other Asian markets, as MSCI rebalancing provided a late-session boost to hold the 46,000-point mark.
3037, 3406
Electronic Technology · economic_daily · 2026-08-31
Optical lens maker GSEO reported strong July earnings of NT$2.92 per share, as the company pivots toward CPO technology and benefits from new iPhone orders.
3406
Electronic Technology · economic_daily · 2026-08-31
Strong export data and high AI order visibility bolster Taiwan's economic outlook, with Silicon Photonics and CPO emerging as key growth drivers for the sector.